SINOMAB BIO-B (03681) surged over 15%, rising 18.42% to HK$2.7 at the time of writing, with trading volume of HK$6,108.39.

The company recently released its interim results for the six months ended June 30, 2025, showing total other income and gains of approximately RMB 9.802 million, representing a 126.95% year-on-year increase. Research and development costs amounted to RMB 32.74 million during the period. The loss for the period decreased by RMB 40.8 million, primarily due to reduced R&D laboratory consumables and experimental costs incurred in preparation for the Sucutumumab BLA and commercialization, as well as decreased employment costs.

According to the announcement, the Group's clinical trial programs and pipeline development have achieved significant progress, including advances in the company's two core products, Sucutumumab and SM17. Recently, Sucutumumab achieved breakthrough results in preclinical in vivo studies for the treatment of systemic lupus erythematosus (SLE).

Leveraging its unique advantages of "regulating autoimmune networks through B-cell interactions + organ damage protection benefits," Sucutumumab not only significantly reduces anti-double-stranded DNA (anti-dsDNA) antibody levels but also demonstrates superior performance compared to existing drugs in improving lupus nephritis (LN) proteinuria and renal pathological damage.